CH0499880968 - Common Stock
ADC THERAPEUTICS SA
NYSE:ADCT (9/27/2023, 12:21:07 PM)
0.861
-0.05 (-5.38%)
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 317 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
ADC THERAPEUTICS SA
Biopole, route de la Corniche 3B
Epalinges VAUD 1066
P: 41216530200.0
CEO: Christopher Martin
Employees: 317
Website: https://adctherapeutics.com/
Shares of ADC Therapeutics (ADCT) tumbled 3.4% on Tuesday after the company disclosed that it was withdrawing its 2023 revenue outlook.ADT added that it was withdrawing its guidance...
LAUSANNE, Schweiz, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) hat heute bekanntgegeben, dass Ameet Mallik, Chief Executive...
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer,...
LOTIS-5: Aktualisierte Sicherheitsergebnisse der Phase-3-Studie zeigen eine 80%ige ORR, 50%ige CR-Rate und eine mediane DoR von 8 Monaten ohne neue...
Here you can normally see the latest stock twits on ADCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: